Albumin stabilized prostacyclin
AssigneeThe Upjohn Company
InventorFrancis A. Fitzpatrick
Life of this patent
Estimating the term…
Abstract
The present invention provides novel formulations of prostacyclin suitable for parenteral administration and methods for making and using these formulations. These novel formulations include a pharmaceutically acceptable stabilizing concentration of albumin as a constituent thereof. Such novel formulations of prostacyclin are useful for its conventional pharmacological and therapeutical purposes, most to inhibition of blood platelet aggregation.
Claims4
In a method consisting essentially of administering prostacyclin to a mammal in a formulation suitable for parenteral administration, the improvement which comprises:
- employing as an excipient in said formulation in a pharmaceutically acceptable, stabilizing concentration albumin derived from serum obtained from the species of which said mammal is a member.
In a composition consisting essentially of a formulation of prostacyclin suitable for parenteral administration, the improvement which comprises:
- albumin derived from serum obtained from the species of which said mammal is a member, employed as an excipient in said formulation in a pharmaceutically acceptable, stabilizing concentration.
A method of stabilizing prostacyclin in a formulation suitable for parenteral administration to a mammal, which comprises
- (1) preparing a conventional pharmaceutical diluent for said formulation,
- (2) adding to said conventional diluent a pharmaceutically acceptable, stabilizing concentration of albumin derived from serum obtained from the species of which said mammal is a member, thereby preparing a stabilizing diluent, and
- (3) combining with a quantity of said stabilizing diluent an amount of a pharmacologically acceptable salt of prostacyclin whereby a predetermined, pharmaceutically-acceptable concentration of prostacyclin is obtained in the resulting solution.
A formulation of prostacyclin suitable for parenteral administration to a mammal, which comprises:
- (1) a quantity of a conventional pharmaceutical diluent for said formulation,
- (2) an amount of albumin derived from serum obtained from the species of which said mammal is a member,
- which when combined with said quantity of conventional diluent yields a stabilizing diluent wherein said albumin is present in a pharmaceutically acceptable, stabilizing concentration;
- and
- (3) an amount of a pharmacologically acceptable salt of prostacyclin, which when combined with said stabilizing diluent yields a predetermined, pharmaceutically-acceptable concentration of prostacyclin in the resulting solution.
Dependencies are inferred from the claim text.